The iron chelator deferiprone improves the phenotype in a mouse model of tauopathy

Manuscript Number: 

20-0551R1

Author(s): 
Paul A. Adlard, Ashley I. Bush, Larissa Lago, Stuart D. Portbury, Shalini S. Rao

Disclosures

Paul A. Adlard

  • Consulting Fees:
    I am a paid consultant to Alterity Therapeutics. This company is focussed on the use of metal modulation for the treatment of neurodegenerative diseases. This company had no role in this manuscript.
    Equity:
    I am a shareholder (and also have stock options) in Alterity Therapeutics. This company is focussed on the use of metal modulation for the treatment of neurodegenerative diseases. This company had no role in this manuscript.

Ashley I. Bush

  • Consulting Fees:
    Consulting fees from Collaborative Medicinal Development Pty Ltd
    Equity:
    Equity in Alterity Ltd, Cogstate Ltd, Mesoblast Ltd, Brighton Biosciences Ltd, profit share in Collaborative Medicinal Development Pty Ltd

Larissa Lago

  • Nothing to Disclose

Stuart D. Portbury

  • Nothing to Disclose

Shalini S. Rao

  • Nothing to Disclose